In vivo, OV-IL15C and EGFR-CAR NK-cell therapy demonstrated a synergistic effect, reducing tumor burden post-treatment on day 15, prolonging survival, and generating 25% of long-term surviving mice (>50 days) in a GBM30 PDX mouse model. Here, EGFR is linked to neoplasm.